Clinical outcome of patients with diabetes presenting with ST-elevation myocardial infarction and treated with concomitant use of glycoprotein IIb/IIIa inhibitors

Cardiology Journal

Volumn 16, Issue 3, 2009, Pages 234-240

  Kralev, Stefan ^a,b   Krause, Barbara ^a   Papavassiliu, Theano ^a   Lang, Siegfried ^a   Haghi, Dariusch ^a   Kälsch, Thorsten ^a   Dempfle, Carl Erik ^a   Borggrefe, Martin ^a   Süselbeck, Tim ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b NONE   (Germany)

Author keywords

Diabetes mellitus; GP IIb IIIa; Myocardial infarction; Percutaneous coronary intervention; ST elevation myocardial infarction

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; HEPARIN; TIROFIBAN; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR;

ADULT; AGED; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DISEASE COURSE; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBESITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; RISK FACTOR; ST ELEVATION MYOCARDIAL INFARCTION; AGE; ANGIOCARDIOGRAPHY; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; DRUG ANTAGONISM; INSTRUMENTATION; MIDDLE AGED; PRACTICE GUIDELINE; RADIOGRAPHY; STENT; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGE FACTORS; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR DISEASES; CORONARY ANGIOGRAPHY; DIABETES COMPLICATIONS; FEMALE; HOSPITAL MORTALITY; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OBESITY; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 67650469073     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Kenn H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia, 2001; 44: S14-S21.
2. Gasior M, Pres D, Stasik-Pres G et al. Effect of blood glucose levels on prognosis in acute myocardial infarction in patients with and without diabetes, undergoing percutaneous coronary intervention. Cardiol J, 2008; 15: 422-430.
3. Hasdai D, Granger CB, Srivatsa SS, Criger DA, Ellis SG, Califf RM. Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: lessons from the GUSTO-IIb Angioplasty Substudy. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes. J Am Coll Cardiol, 2000; 35: 1502-1512.
4. Granger CB, Califf RM, Young S et al. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents: the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. J Am Coll Cardiol, 1993; 21: 920-955.
5. Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, Currier JW. Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation, 1996; 94: 1818-1825.
6. Nahser PJ Jr, Brown RE, Oskarsson H, Winniford MD, Rossen JD. Maximal coronary flow reserve and metabolic coronary vasodilation in patients with diabetes mellitus. Circulation, 1995; 91: 635-640.
7. Nitenberg A, Valensi P, Sachs R, Dali M, Aptecar E, Attali JR. Impairment of coronary vascular reserve and ACh-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. Diabetes, 1993; 42: 1017-1025.
8. Antman EM, Hand M, Armstrong PW et al. 2007 Focused Update of the ACC/ AHA 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction. Circulation, 2008; 117: 296-329.
9. The TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial: phase I findings. N Engl J Med, 1985; 312: 932-936.
10. Bierman EL, George L. Duff memorial lecture. Atherogenesis in diabetes. Arterioscler Thromb, 1992; 12: 647-656.
11. Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev, 1987; 3: 463-524.
12. Malmberg K, Yusuf S, Gerstein HC et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q - wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation, 2000; 102: 1014-1019.
13. Gitt AK, Schiele R, Wienbergen H et al. Intensive treatment of coronary artery disease in diabetic patients in clinical practice: results of the MITRA study. Acta Diabetol, 2003; 40(Suppl 2): S343-S347.
14. Jacoby RM, Nesto RW. Acute myocardial infarction in the diabetic patient: Pathophysiology, clinical course and prognosis. J Am Coll Cardiol, 1992; 20: 736-744.
15. Waldecker B, Waas W, Haberbosch W et al. Type 2 diabetes and acute myocardial infarction. Angiographic findings and results of an invasive therapeutic approach in type 2 diabetic versus non - diabetic patients. Diabetes Care, 1999; 22: 1832-1838.
16. Angeja BG, de Lemos J, Murphy SA et al. TIMI study group. Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy Am Heart J, 2002; 144: 649-656.
17. Otel I, Ledru F, Danchin N. Ischemic heart disease in type 2 diabetes. Metabolism 2003; 52(8 Suppl 1): 6-12
18. Gibson CM, Cannon CP, Murphy SA, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation, 2000; 101: 125-130.
19. Schroder R, Dissmann R, Bruggemann T et al. Extent of early ST-segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Cardiol, 1994; 24: 384-391.
20. Calles-Escandon J, Mirza SA, Sobel BE, Schneider DJ. Induction of hyperinsulinemia combined with hyperglycemia and hyper-triglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes, 1998; 47: 290-293.
21. Davi G, Gresele P, Violi F, et al. Diabetes mellitus, hypercholesterolemia and hypertension, but not vascular disease per se, are associated with persistent platelet activation in vivo: evidence derived from the study of peripheral arterial disease. Circulation, 1997; 96: 69-75.
22. Knobler H, Savion N, Shenkman B, Kotev-Emeth S, Varon D. Shear-induced platelet adhesion and aggregation on subendothelium are increased in diabetic patients. Thromb Res, 1998; 90: 181-190.
23. Shukla SD, Paul A, Klachko DM. Hypersensitivity of diabetic human platelets to platelet activating factor. Thromb Res, 1992; 66: 239-246.
24. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Circulation, 1998; 97: 2386-2395.
25. Tschoepe D, Roesen P, Kaufmann L et al. Evidence for abnormal platelet glycoprotein expression in diabetes mellitus. Eur J Clin Invest, 1990; 20: 166-170.
26. Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol, 2000; 35: 922-928.
27. Topol EJ, Mark DB, Lincoff AM, Cohen E, Burton J, Kleiman N. Outcomes at one year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial. EPISTENT Investigators Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet, 1999; 354: 2019-2024.
28. Theroux P, Alexander J Jr, Pharand C, et al. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: Results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Circulation, 2000; 102: 2466-2472.
29. Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet, 2006; 367: 579-588.
30. Montalescot G, Antoniucci D, Kastrati A et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: A European meta-analysis on individual patients' data with long-term follow-up. Eur Heart J, 2007; 28: 443-449.